Isomorphic Labs raises $2.1 billion in Series B funding
Led by Thrive Capital, with participation from Alphabet, GV, and new investors.
See the latest news and media coverage for Isomorphic Labs. We track all announcements, press releases, and industry mentions in real time, all in one place.
AI-driven drug discovery company
isomorphiclabs.comLast updated
In short: Isomorphic Labs secured $2.1 billion in Series B funding and prepared for human clinical trials of its AI-driven drug candidates.
Led by Thrive Capital, with participation from Alphabet, GV, and new investors.
The award recognizes their work with Novartis on AI-driven drug discovery. They aim to accelerate new medicines to patients.
The engine outperforms benchmarks, models induced fits and cryptic pockets, and explores new chemical space for drug design.
IsoDDE surpasses AlphaFold 3 in protein-ligand prediction, binding affinities, and pocket identification, advancing AI-driven drug discovery.
Earlier this year, DeepMind spin-off Isomorphic Labs began preparing the first human clinical trials of drugs designed with its AI systems.
Isomorphic Labs raises $2.1B in Series B funding led by Thrive Capital to scale its AI-driven drug design engine and expand its global operations.
Google's head of AI, Demis Hassabis, will step down from his current role to become Alphabet's chief scientist amid a reshuffling at DeepMind that will...
The artificial intelligence system largely accomplished the task it was built to solve, and researchers outside DeepMind have already been carrying its...
Track Isomorphic Labs and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Isomorphic Labs and other trending companies.